{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import requests\n",
    "from bs4 import BeautifulSoup\n",
    "from dateutil import parser\n",
    "import pandas as pd\n",
    "import datetime\n",
    "import re"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "def search_page(vol, page):\n",
    "    print(f'Scraping from volumn {vol} page {page}', end = \":\\t\")\n",
    "    url = f\"https://nejm.jp/abstract/vol{vol}.p{page}\"\n",
    "    headers = {'User-Agent': 'Mozilla/5.0 (Macintosh; Intel Mac OS X 10_11_6) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/61.0.3163.100 Safari/537.36'}\n",
    "    page = requests.get(url, headers = headers)\n",
    "    soup = BeautifulSoup(page.content)\n",
    "    results = [parag.text for parag in soup.select(\".add\")]\n",
    "    try:\n",
    "        new = soup.select(\"#sectionWrap a\")[0].attrs['href']\n",
    "    except Exception:\n",
    "        print(\"0 training sets added.\")\n",
    "        return []\n",
    "    en_page = requests.get(new, headers = headers)\n",
    "    en_soup = BeautifulSoup(en_page.content)\n",
    "    en_results = [parag.text for parag in en_soup.select(\"#article_Abstract .f-body\")]\n",
    "    if not en_results:\n",
    "        en_results = [parag.text for parag in en_soup.select(\"#article_body .f-body\")]\n",
    "    tmp = [(url, jp, new, en) for jp, en in zip(results, en_results)]\n",
    "    print(f\"{len(tmp)} training sets added.\")\n",
    "    return tmp\n",
    "\n",
    "def search_volumn(vol, num):\n",
    "    url = f\"https://nejm.jp/contents/idx.vol{vol}.no{num}\"\n",
    "    headers = {'User-Agent': 'Mozilla/5.0 (Macintosh; Intel Mac OS X 10_11_6) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/61.0.3163.100 Safari/537.36'}\n",
    "    page = requests.get(url, headers = headers)\n",
    "    soup = BeautifulSoup(page.content)\n",
    "    results = [int(re.match('/abstract/vol\\d+.p(\\d+)', parag.attrs['href'])[1]) for parag in soup.select(\".link02 a\")]\n",
    "    if not soup.select(\".pageNum\"):\n",
    "        raise Exception(\"No items found.\")\n",
    "    return sum([search_page(vol, page) for page in results], [])\n",
    "\n",
    "def search_all(vol_start = 336, vol_end = None):\n",
    "    vol, num = vol_start, 1\n",
    "    total_results = []\n",
    "    vol_results = []\n",
    "    while not vol_end or vol <= vol_end:\n",
    "        try:\n",
    "            vol_results += search_volumn(vol, num)\n",
    "            num += 1\n",
    "        except Exception as e:\n",
    "            if num == 1:\n",
    "                break\n",
    "            if vol_results:\n",
    "                pd.DataFrame(vol_results, columns = ['jp_url', 'jp_txt', 'en_url', 'en_txt']).to_csv(f'jp_en/vol_{vol}.csv', index = False)\n",
    "                total_results += vol_results\n",
    "                vol_results = []\n",
    "            vol, num = vol + 1, 1\n",
    "    return total_results"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Scraping from volumn 383 page 13:\t4 training sets added.\n",
      "Scraping from volumn 383 page 24:\t4 training sets added.\n",
      "Scraping from volumn 383 page 35:\t4 training sets added.\n",
      "Scraping from volumn 383 page 49:\t4 training sets added.\n",
      "Scraping from volumn 383 page 109:\t4 training sets added.\n",
      "Scraping from volumn 383 page 120:\t4 training sets added.\n",
      "Scraping from volumn 383 page 129:\t4 training sets added.\n",
      "Scraping from volumn 383 page 141:\t4 training sets added.\n",
      "Scraping from volumn 383 page 207:\t4 training sets added.\n",
      "Scraping from volumn 383 page 218:\t4 training sets added.\n",
      "Scraping from volumn 383 page 229:\t4 training sets added.\n",
      "Scraping from volumn 383 page 240:\t4 training sets added.\n",
      "Scraping from volumn 383 page 309:\t4 training sets added.\n",
      "Scraping from volumn 383 page 321:\t4 training sets added.\n",
      "Scraping from volumn 383 page 334:\t4 training sets added.\n",
      "Scraping from volumn 383 page 347:\t4 training sets added.\n",
      "Scraping from volumn 383 page 359:\t4 training sets added.\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[('https://nejm.jp/abstract/vol383.p13',\n",
       "  'アフリカの資源の少ない環境での，肺炎の小児に対する抗菌薬の適切な治療期間に関するエビデンスは不足している．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1912400',\n",
       "  'Evidence regarding the appropriate duration of treatment with antibiotic agents in children with pneumonia in low-resource settings in Africa is lacking.'),\n",
       " ('https://nejm.jp/abstract/vol383.p13',\n",
       "  'マラウイのリロングウェで，胸部陥凹を伴う肺炎（持続期間が 14 日間未満の咳嗽，または呼吸困難に，明らかな胸壁の陥凹を伴う；年齢に比した多呼吸の有無は問わない）の小児に対するアモキシシリンの 3 日間の投与は，5 日間の投与よりも有効性が低いかどうかを明らかにするため，二重盲検無作為化対照非劣性試験を行った．胸部陥凹を伴う肺炎を有する生後 2～59 ヵ月のヒト免疫不全ウイルス（HIV）陰性の小児を，アモキシシリンを 1 日 2 回，3 日間投与する群と 5 日間投与する群に無作為に割り付けた．児は 14 日間追跡した．主要転帰は 6 日目までの治療失敗とした．3 日間レジメンの 5 日間レジメンに対する非劣性は，3 日間群の治療失敗例の割合が 5 日間群の 1.5 倍を超えない場合に示されるものとした．事前に規定した副次的解析には，14 日目までの治療失敗または再発の評価を含めた．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1912400',\n",
       "  'We conducted a double-blind, randomized, controlled, noninferiority trial in Lilongwe, Malawi, to determine whether treatment with amoxicillin for 3 days is less effective than treatment for 5 days in children with chest-indrawing pneumonia (cough lasting <14 days or difficulty breathing, along with visible indrawing of the chest wall with or without fast breathing for age). Children not infected with human immunodeficiency virus (HIV) who were 2 to 59 months of age and had chest-indrawing pneumonia were randomly assigned to receive amoxicillin twice daily for either 3 days or 5 days. Children were followed for 14 days. The primary outcome was treatment failure by day 6; noninferiority of the 3-day regimen to the 5-day regimen would be shown if the percentage of children with treatment failure in the 3-day group was no more than 1.5 times that in the 5-day group. Prespecified secondary analyses included assessment of treatment failure or relapse by day 14.'),\n",
       " ('https://nejm.jp/abstract/vol383.p13',\n",
       "  '2016 年 3 月 29 日～2019 年 4 月 1 日に 3,000 例が無作為化され，1,497 例が 3 日間群，1,503 例が 5 日間群に割り付けられた．6 日目のデータを入手しえた児のうち，治療失敗は 3 日間群の 5.9%（1,442 例中 85 例）と 5 日間群の 5.2%（1,456 例中 75 例）に発生し（補正後の群間差 0.7 パーセントポイント，95%信頼区間 [CI] －0.9～2.4），3 日間レジメンの 5 日間レジメンに対する非劣性の基準を満たす結果であった．14 日目のデータを入手しえた児のうち，6 日目までの治療失敗または 14 日目までの再発は，3 日間群の 1,411 例中 176 例（12.5%）と 5 日間群の 1,429 例中 154 例（10.8%）に発生した（群間差 1.7 パーセントポイント，95% CI －0.7～4.1）．重篤な有害事象が発現した児の割合は 2 群で同程度であった（3 日間群 9.8%，5 日間群 8.8%）．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1912400',\n",
       "  'From March 29, 2016, to April 1, 2019, a total of 3000 children underwent randomization: 1497 children were assigned to the 3-day group, and 1503 to the 5-day group. Among children with day 6 data available, treatment failure had occurred in 5.9% in the 3-day group (85 of 1442 children) and in 5.2% (75 of 1456) in the 5-day group (adjusted difference, 0.7 percentage points; 95% confidence interval [CI], −0.9 to 2.4) — a result that satisfied the criterion for noninferiority of the 3-day regimen to the 5-day regimen. Among children with day 14 data available, 176 of 1411 children (12.5%) in the 3-day group and 154 of 1429 (10.8%) in the 5-day group had had treatment failure by day 6 or relapse by day 14 (between-group difference, 1.7 percentage points; 95% CI, −0.7 to 4.1). The percentage of children with serious adverse events was similar in the two groups (9.8% in the 3-day group and 8.8% in the 5-day group).'),\n",
       " ('https://nejm.jp/abstract/vol383.p13',\n",
       "  'HIV 陰性のマラウイの小児では，胸部陥凹を呈する肺炎に対するアモキシシリンによる 3 日間の治療は，5 日間の治療に対して非劣性であった．（ビル&メリンダ・ゲイツ財団から研究助成を受けた．ClinicalTrials.gov 登録番号 NCT02678195）',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1912400',\n",
       "  'In HIV-uninfected Malawian children, treatment with amoxicillin for chest-indrawing pneumonia for 3 days was noninferior to treatment for 5 days. (Funded by the Bill and Melinda Gates Foundation; ClinicalTrials.gov number, NCT02678195.)'),\n",
       " ('https://nejm.jp/abstract/vol383.p24',\n",
       "  '世界保健機関（WHO）は，頻呼吸を伴う肺炎患者に対して経口アモキシシリンを推奨しているが，試験のデータから，この病態の治療にアモキシシリンを使用しない場合も，使用した場合と比較して非劣性である可能性が示されている．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1911998',\n",
       "  'The World Health Organization (WHO) recommends oral amoxicillin for patients who have pneumonia with tachypnea, yet trial data indicate that not using amoxicillin to treat this condition may be noninferior to using amoxicillin.'),\n",
       " ('https://nejm.jp/abstract/vol383.p24',\n",
       "  'パキスタン・カラチの低所得地域にある一次医療センターで，小児を対象とした二重盲検無作為化プラセボ対照非劣性試験を行った．頻呼吸を伴う非重症肺炎の WHO 基準を満たす生後 2～59 ヵ月の小児を，アモキシシリン懸濁液 50 mg/mL（実薬対照）を 3 日間投与する群と，用量をマッチさせたプラセボ（試験レジメン）を投与する群に無作為に割り付けた．投与量は WHO の体重区分別に規定した（体重 4 kg 以上 10 kg 未満は 500 mg を 12 時間ごと，10 kg 以上 14 kg 未満は 1,000 mg を 12 時間ごと，14 kg 以上 20 kg 未満は 1,500 mg を 12 時間ごと）．主要転帰は，アモキシシリンまたはプラセボの 3 日間の投与期間中の治療失敗とした．事前に規定した非劣性マージンは 1.75 パーセントポイントであった．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1911998',\n",
       "  'We conducted a double-blind, randomized, placebo-controlled noninferiority trial involving children at primary health care centers in low-income communities in Karachi, Pakistan. Children who were 2 to 59 months of age and who met WHO criteria for nonsevere pneumonia with tachypnea were randomly assigned to a 3-day course of a suspension of amoxicillin (the active control) of 50 mg per milliliter or matched volume of placebo (the test regimen), according to WHO weight bands (500 mg every 12 hours for a weight of 4 to <10 kg, 1000 mg every 12 hours for a weight of 10 to <14 kg, or 1500 mg every 12 hours for a weight of 14 to <20 kg). The primary outcome was treatment failure during the 3-day course of amoxicillin or placebo. The prespecified noninferiority margin was 1.75 percentage points.'),\n",
       " ('https://nejm.jp/abstract/vol383.p24',\n",
       "  '2014 年 11 月 9 日～2017 年 11 月 30 日に 4,002 例が無作為化された（プラセボ群 1,999 例，アモキシシリン群 2,003 例）．per-protocol解析では，治療失敗率はプラセボ群で 4.9%（1,927 例中 95 例），アモキシシリン群で 2.6%（1,929 例中 51 例）であった（群間差 2.3 パーセントポイント，95%信頼区間 [CI] 0.9～3.7）．intention-to-treat 解析でも結果は同様であった．発熱と喘鳴は治療失敗の予測因子であった．1 件の治療失敗を予防するために必要な治療数は 44（95% CI 31～80）であった．各群 1 例（0.1%未満）が死亡した．再発はプラセボ群の 40 例（2.2%）とアモキシシリン群の 58 例（3.1%）に認められた．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1911998',\n",
       "  'From November 9, 2014, through November 30, 2017, a total of 4002 children underwent randomization (1999 in the placebo group and 2003 in the amoxicillin group). In the per-protocol analysis, the incidence of treatment failure was 4.9% among placebo recipients (95 of 1927 children) and 2.6% among amoxicillin recipients (51 of 1929 children) (between-group difference, 2.3 percentage points; 95% confidence interval [CI], 0.9 to 3.7). Results were similar in the intention-to-treat analysis. The presence of fever and wheeze predicted treatment failure. The number needed to treat to prevent one treatment failure was 44 (95% CI, 31 to 80). One patient (<0.1%) in each group died. Relapse occurred in 40 children (2.2%) in the placebo group and in 58 children (3.1%) in the amoxicillin group.'),\n",
       " ('https://nejm.jp/abstract/vol383.p24',\n",
       "  '5 歳未満の非重症肺炎の小児では，治療失敗の頻度はプラセボ群のほうがアモキシシリン群よりも高く，差はプラセボの非劣性マージンを満たさなかった．（[英国国際開発省，英国医学研究評議会，ウェルカムトラストの] 共同グローバルヘルス試験計画ほかから研究助成を受けた．RETAPP 試験：ClinicalTrials.gov 登録番号 NCT02372461）',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1911998',\n",
       "  'Among children younger than 5 years of age with nonsevere pneumonia, the frequency of treatment failure was higher in the placebo group than in the amoxicillin group, a difference that did not meet the noninferiority margin for placebo. (Funded by the Joint Global Health Trials Scheme [of the Department for International Development, Medical Research Council, and Wellcome] and others; RETAPP ClinicalTrials.gov number, NCT02372461.)'),\n",
       " ('https://nejm.jp/abstract/vol383.p35',\n",
       "  '慢性閉塞性肺疾患（COPD）に対する吸入ステロイド，長時間作用性抗コリン薬（LAMA），長時間作用性β2 刺激薬（LABA）の 3 剤による固定用量レジメンは，吸入ステロイドは 1 用量で検討されているが，2 用量では検討されていない．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1916046',\n",
       "  'Triple fixed-dose regimens of an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β2-agonist (LABA) for chronic obstructive pulmonary disease (COPD) have been studied at single dose levels of inhaled glucocorticoid, but studies at two dose levels are lacking.'),\n",
       " ('https://nejm.jp/abstract/vol383.p35',\n",
       "  '中等症～最重症の COPD を有し，過去 1 年間に増悪が 1 回以上あった患者を対象に，2 用量の吸入ステロイドで 3 剤併用療法の有効性と安全性を評価する 52 週間の第 3 相無作為化試験を行った．患者を，1 日 2 回吸入の 3 剤併用療法の 2 群（吸入ステロイド [ブデソニド 320μg または 160μg]，LAMA [グリコピロニウム 18μg]，LABA [ホルモテロール 9.6μg]）と，2 剤併用療法の 2 群（グリコピロニウム 18μg＋ホルモテロール 9.6μg，またはブデソニド 320μg＋ホルモテロール 9.6μg）に 1：1：1：1 の割合で割り付けた．主要評価項目は，中等度または重度の COPD 増悪の年間発生率（1 年間の 1 例あたりの平均回数の推定）とし，投与中のデータのみを用いた修正 intention-to-treat 集団で解析した．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1916046',\n",
       "  'In a 52-week, phase 3, randomized trial to evaluate the efficacy and safety of triple therapy at two dose levels of inhaled glucocorticoid in patients with moderate-to-very-severe COPD and at least one exacerbation in the past year, we assigned patients in a 1:1:1:1 ratio to receive twice-daily inhaled doses of triple therapy (inhaled glucocorticoid [320 μg or 160 μg of budesonide], a LAMA [18 μg of glycopyrrolate], and a LABA [9.6 μg of formoterol]) or one of two dual therapies (18 μg of glycopyrrolate plus 9.6 μg of formoterol or 320 μg of budesonide plus 9.6 μg of formoterol). The primary end point was the annual rate (the estimated mean number per patient per year) of moderate or severe COPD exacerbations, as analyzed in the modified intention-to-treat population with the use of on-treatment data only.'),\n",
       " ('https://nejm.jp/abstract/vol383.p35',\n",
       "  '修正 intention-to-treat 集団は 8,509 例であった．中等度または重度の増悪の年間発生率は，ブデソニド 320μg による 3 剤併用療法群（2,137 例）で 1.08，ブデソニド 160μg による 3 剤併用療法群（2,121 例）で 1.07，グリコピロニウム＋ホルモテロール群（2,120 例）で 1.42，ブデソニド＋ホルモテロール群（2,131 例）で 1.24 であった．ブデソニド 320μg による 3 剤併用療法群は，発生率がグリコピロニウム＋ホルモテロール群よりも有意に低く（24%低下，率比 0.76，95%信頼区間 [CI] 0.69～0.83，P＜0.001），またブデソニド＋ホルモテロール群よりも有意に低かった（13%低下，率比 0.87，95% CI 0.79～0.95，P＝0.003）．同様に，ブデソニド 160μg による 3 剤併用療法群は，発生率がグリコピロニウム＋ホルモテロール群よりも有意に低く（25%低下，率比 0.75，95% CI 0.69～0.83，P＜0.001），またブデソニド＋ホルモテロール群よりも有意に低かった（14%低下，率比 0.86，95% CI 0.79～0.95，P＝0.002）．すべての有害事象の発現率は 4 群で同程度であり（範囲 61.7～64.5%），確定された肺炎の発生率は，吸入ステロイドを使用した群で 3.5～4.5%，グリコピロニウム＋ホルモテロール群で 2.3%であった．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1916046',\n",
       "  'The modified intention-to-treat population comprised 8509 patients. The annual rates of moderate or severe exacerbations were 1.08 in the 320-μg–budesonide triple-therapy group (2137 patients), 1.07 in the 160-μg–budesonide triple-therapy group (2121 patients), 1.42 in the glycopyrrolate–formoterol group (2120 patients), and 1.24 in the budesonide–formoterol group (2131 patients). The rate was significantly lower with 320-μg–budesonide triple therapy than with glycopyrrolate–formoterol (24% lower: rate ratio, 0.76; 95% confidence interval [CI], 0.69 to 0.83; P<0.001) or budesonide–formoterol (13% lower: rate ratio, 0.87; 95% CI, 0.79 to 0.95; P=0.003). Similarly, the rate was significantly lower with 160-μg–budesonide triple therapy than with glycopyrrolate–formoterol (25% lower: rate ratio, 0.75; 95% CI, 0.69 to 0.83; P<0.001) or budesonide–formoterol (14% lower: rate ratio, 0.86; 95% CI, 0.79 to 0.95; P=0.002). The incidence of any adverse event was similar across the treatment groups (range, 61.7 to 64.5%); the incidence of confirmed pneumonia ranged from 3.5 to 4.5% in the groups that included inhaled glucocorticoid use and was 2.3% in the glycopyrrolate–formoterol group.'),\n",
       " ('https://nejm.jp/abstract/vol383.p35',\n",
       "  'ブデソニド（160μg または 320μg），グリコピロニウム，ホルモテロールを 1 日 2 回投与する 3 剤併用療法では，グリコピロニウム＋ホルモテロールまたはブデソニド＋ホルモテロールと比較して，中等度または重度の COPD 増悪の発生率が低下した．（アストラゼネカ社から研究助成を受けた．ETHOS 試験：ClinicalTrials.gov 登録番号 NCT02465567）',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1916046',\n",
       "  'Triple therapy with twice-daily budesonide (at either the 160-μg or 320-μg dose), glycopyrrolate, and formoterol resulted in a lower rate of moderate or severe COPD exacerbations than glycopyrrolate–formoterol or budesonide–formoterol. (Funded by AstraZeneca, ETHOS ClinicalTrials.gov number, NCT02465567.)'),\n",
       " ('https://nejm.jp/abstract/vol383.p49',\n",
       "  '在胎期間は，早産児における新生児死亡（生後 28 日以内の死亡）の主な決定因子である．在胎期間とアプガースコアの組合せによる新生児死亡リスクへの影響は明らかにされていない．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1915075',\n",
       "  'Gestational age is the major determinant of neonatal death (death within the first 28 days of life) in preterm infants. The joint effect of gestational age and Apgar score on the risk of neonatal death is unknown.'),\n",
       " ('https://nejm.jp/abstract/vol383.p49',\n",
       "  'スウェーデンの医療出生登録のデータを用いて，1992～2016 年に出生した早産児（在胎 22 週 0 日～36 週 6 日）113,300 例を同定した．在胎期間（在胎 22～24 週，25～27 週，28～31 週，32～34 週，35～36 週）で層別化した解析で，新生児死亡の補正後の相対リスクと，新生児死亡率の絶対値の差（出生 100 例あたりの新生児の超過死亡数）を，出生 5 分後と 10 分後のアプガースコアと，5 分後から 10 分後までのアプガースコアの変化に基づいて推定した．スコアは 0～10 で，高いほど新生児の身体状態が良好であることを示す．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1915075',\n",
       "  'Using data from the Swedish Medical Birth Register, we identified 113,300 preterm infants (22 weeks 0 days to 36 weeks 6 days of gestation) born from 1992 through 2016. In analyses stratified according to gestational age (22 to 24 weeks, 25 to 27 weeks, 28 to 31 weeks, 32 to 34 weeks, and 35 or 36 weeks), we estimated adjusted relative risks of neonatal death and absolute rate differences in neonatal mortality (i.e., the excess number of neonatal deaths per 100 births) according to the Apgar scores at 5 and 10 minutes and according to the change in the Apgar score between 5 minutes and 10 minutes. Scores range from 0 to 10, with higher scores indicating a better physical condition of the newborn.'),\n",
       " ('https://nejm.jp/abstract/vol383.p49',\n",
       "  '1,986 件（1.8%）の新生児死亡があった．新生児死亡の発生率は 0.2%（在胎 36 週）～76.5%（在胎 22 週）の範囲であった．在胎期間のすべての層において，アプガースコアが低いことは，新生児死亡の相対リスクが高いことと，新生児死亡率の絶対値の差が大きいことに関連していた．たとえば在胎 28～31 週に出生した児では，5 分後のアプガースコアに基づく補正後の絶対値の差は，スコア 9～10 の児を参照群とすると，スコア 0～1 で 51.7（95%信頼区間 [CI] 38.1～65.4），2～3 で 25.5（95% CI 18.3～32.8），4～6 で 7.1（95% CI 5.1～9.1），7～8 で 1.2（95% CI 0.5～1.9）であった．5 分後から 10 分後までにアプガースコアが上昇した場合，スコアに変化がない場合と比較して新生児死亡率がより低いことに関連していた．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1915075',\n",
       "  'There were 1986 neonatal deaths (1.8%). The incidence of neonatal death ranged from 0.2% (at 36 weeks of gestation) to 76.5% (at 22 weeks of gestation). Lower Apgar scores were associated with higher relative risks of neonatal death and greater absolute rate differences in neonatal mortality in all gestational-age strata. For example, among infants born at 28 to 31 weeks, the adjusted absolute rate differences according to the 5-minute Apgar score, with those who had a score of 9 or 10 serving as the reference group, were 51.7 (95% confidence interval [CI], 38.1 to 65.4) for a score of 0 or 1, 25.5 (95% CI, 18.3 to 32.8) for a score of 2 or 3, 7.1 (95% CI, 5.1 to 9.1) for a score of 4 to 6, and 1.2 (95% CI, 0.5 to 1.9) for a score of 7 or 8. An increase in the Apgar score between 5 minutes and 10 minutes was associated with lower neonatal mortality than a stable Apgar score.'),\n",
       " ('https://nejm.jp/abstract/vol383.p49',\n",
       "  'この研究では，出生 5 分後と 10 分後のアプガースコアから，在胎期間のすべての層の早産児で新生児の生存に関する予後情報が得られた．（スウェーデン保健労働生活福祉研究評議会，カロリンスカ研究所から研究助成を受けた．）',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1915075',\n",
       "  'In this study, Apgar scores at 5 and 10 minutes provided prognostic information about neonatal survival among preterm infants across gestational-age strata. (Funded by the Swedish Research Council for Health, Working Life, and Welfare and Karolinska Institutet.)'),\n",
       " ('https://nejm.jp/abstract/vol383.p109',\n",
       "  'トフェルセン（tofersen）は，スーパーオキシドジスムターゼ 1（SOD1）メッセンジャー RNA の分解を仲介し，SOD1 蛋白合成を抑制するアンチセンスオリゴヌクレオチドである．SOD1 変異に起因する筋萎縮性側索硬化症（ALS）の治療にトフェルセンの髄腔内投与が検討されている．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa2003715',\n",
       "  'Tofersen is an antisense oligonucleotide that mediates the degradation of superoxide dismutase 1 (SOD1) messenger RNA to reduce SOD1 protein synthesis. Intrathecal administration of tofersen is being studied for the treatment of amyotrophic lateral sclerosis (ALS) due to SOD1 mutations.'),\n",
       " ('https://nejm.jp/abstract/vol383.p109',\n",
       "  'SOD1 変異に起因する ALS の成人を対象にトフェルセンを評価する第 1・2 相用量漸増試験を行った．4 用量のグループ（20，40，60，100 mg）を設定し，トフェルセンを 12 週の期間に 5 回髄腔内投与する群とプラセボを投与する群に，参加者を 3：1 の割合で無作為に割り付けた．主要評価項目は安全性と薬物動態とした．副次的評価項目は，85 日目における脳脊髄液（髄液）中 SOD1 濃度のベースラインからの変化量とした．臨床機能と肺活量を測定した．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa2003715',\n",
       "  'We conducted a phase 1–2 ascending-dose trial evaluating tofersen in adults with ALS due to SOD1 mutations. In each dose cohort (20, 40, 60, or 100 mg), participants were randomly assigned in a 3:1 ratio to receive five doses of tofersen or placebo, administered intrathecally for 12 weeks. The primary outcomes were safety and pharmacokinetics. The secondary outcome was the change from baseline in the cerebrospinal fluid (CSF) SOD1 concentration at day 85. Clinical function and vital capacity were measured.'),\n",
       " ('https://nejm.jp/abstract/vol383.p109',\n",
       "  '50 例が無作為化され解析の対象となった．48 例が計画されていた 5 回の投与をすべて受けた．腰椎穿刺に関連する有害事象が大部分の参加者で認められた．髄液中の白血球数の増加と蛋白濃度の上昇が，それぞれトフェルセンの投与を受けた参加者の 4 例と 5 例で有害事象として報告された．トフェルセンの投与を受けた参加者のうち，1 例が肺塞栓症で 137 日目に死亡し，1 例が呼吸不全で 152 日目に死亡した．プラセボ群では 1 例が呼吸不全で 52 日目に死亡した．85 日目における髄液中 SOD1 濃度の，ベースラインからの変化量のトフェルセン群とプラセボ群の差は，用量 20 mg では 2 パーセントポイント（95%信頼区間 [CI] －18～27），40 mg では －25 パーセントポイント（95% CI －40～－5），60 mg では －19 パーセントポイント（95% CI －35～2），100 mg では －33 パーセントポイント（95% CI －47～－16）であった．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa2003715',\n",
       "  'A total of 50 participants underwent randomization and were included in the analyses; 48 participants received all five planned doses. Lumbar puncture–related adverse events were observed in most participants. Elevations in CSF white-cell count and protein were reported as adverse events in 4 and 5 participants, respectively, who received tofersen. Among participants who received tofersen, one died from pulmonary embolus on day 137, and one from respiratory failure on day 152; one participant in the placebo group died from respiratory failure on day 52. The difference at day 85 in the change from baseline in the CSF SOD1 concentration between the tofersen groups and the placebo group was 2 percentage points (95% confidence interval [CI], −18 to 27) for the 20-mg dose, −25 percentage points (95% CI, −40 to −5) for the 40-mg dose, −19 percentage points (95% CI, −35 to 2) for the 60-mg dose, and −33 percentage points (95% CI, −47 to −16) for the 100-mg dose.'),\n",
       " ('https://nejm.jp/abstract/vol383.p109',\n",
       "  'SOD1 変異に起因する ALS の成人において，12 週の期間に最大用量のトフェルセンを髄腔内投与した場合，CSF 中 SOD1 濃度が低下した．トフェルセンの投与を受けた参加者の一部には髄液細胞増多が認められた．腰椎穿刺に関連する有害事象が大部分の参加者で認められた．（バイオジェン社から研究助成を受けた．ClinicalTrials.gov 登録番号 NCT02623699，EudraCT 登録番号 2015-004098-33）',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa2003715',\n",
       "  'In adults with ALS due to SOD1 mutations, CSF SOD1 concentrations decreased at the highest concentration of tofersen administered intrathecally over a period of 12 weeks. CSF pleocytosis occurred in some participants receiving tofersen. Lumbar puncture–related adverse events were observed in most participants. (Funded by Biogen; ClinicalTrials.gov number, NCT02623699; EudraCT number, 2015-004098-33.)'),\n",
       " ('https://nejm.jp/abstract/vol383.p120',\n",
       "  '進行性呼吸不全は，新型コロナウイルス感染症（Covid-19）パンデミックにおける主な死因である．この疾患の病態生理への関心が拡大しているにもかかわらず，Covid-19 で死亡する患者の末梢肺の形態学的・分子的変化について明らかにされていることは比較的少ない．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa2015432',\n",
       "  'Progressive respiratory failure is the primary cause of death in the coronavirus disease 2019 (Covid-19) pandemic. Despite widespread interest in the pathophysiology of the disease, relatively little is known about the associated morphologic and molecular changes in the peripheral lung of patients who die from Covid-19.'),\n",
       " ('https://nejm.jp/abstract/vol383.p120',\n",
       "  'Covid-19 で死亡した患者 7 例の剖検時に得られた肺検体を検討し，インフルエンザ A（H1N1）感染に続発する急性呼吸促迫症候群（ARDS）で死亡した患者 7 例の剖検時に得られた肺，および年齢をマッチさせた感染していない対照 10 例の肺と比較した．肺の評価には 7 色免疫組織化学的解析，マイクロ CT 撮影，走査型電子顕微鏡，血管鋳型法，遺伝子発現の直接多重測定を用いた．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa2015432',\n",
       "  'We examined 7 lungs obtained during autopsy from patients who died from Covid-19 and compared them with 7 lungs obtained during autopsy from patients who died from acute respiratory distress syndrome (ARDS) secondary to influenza A(H1N1) infection and 10 age-matched, uninfected control lungs. The lungs were studied with the use of seven-color immunohistochemical analysis, micro–computed tomographic imaging, scanning electron microscopy, corrosion casting, and direct multiplexed measurement of gene expression.'),\n",
       " ('https://nejm.jp/abstract/vol383.p120',\n",
       "  'Covid-19 による呼吸不全で死亡した患者とインフルエンザによる肺炎で死亡した患者の末梢肺の組織パターンは，血管周囲に T 細胞の浸潤を伴うびまん性肺胞傷害であった．Covid-19 患者の肺にはさらに，細胞内における SARS-CoV-2 の存在と細胞膜の破壊を伴う重度の血管内皮損傷という特異な血管像を認めた．Covid-19 患者の肺血管の組織学的解析では，微小血管障害を伴う広範な血栓を認めた．Covid-19 患者では，肺胞毛細血管内の微小血栓の有病率がインフルエンザ患者の 9 倍であった（P＜0.001）．Covid-19 患者の肺では，主に重積血管新生（intussusceptive angiogenesis）の機序を介した新生血管の量がインフルエンザ患者の 2.7 倍であった（P＜0.001）．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa2015432',\n",
       "  'In patients who died from Covid-19–associated or influenza-associated respiratory failure, the histologic pattern in the peripheral lung was diffuse alveolar damage with perivascular T-cell infiltration. The lungs from patients with Covid-19 also showed distinctive vascular features, consisting of severe endothelial injury associated with the presence of intracellular virus and disrupted cell membranes. Histologic analysis of pulmonary vessels in patients with Covid-19 showed widespread thrombosis with microangiopathy. Alveolar capillary microthrombi were 9 times as prevalent in patients with Covid-19 as in patients with influenza (P<0.001). In lungs from patients with Covid-19, the amount of new vessel growth — predominantly through a mechanism of intussusceptive angiogenesis — was 2.7 times as high as that in the lungs from patients with influenza (P<0.001).'),\n",
       " ('https://nejm.jp/abstract/vol383.p120',\n",
       "  'この小規模症例シリーズでは，Covid-19 患者の肺の病理所見と，同等の重症度のインフルエンザウイルス感染患者の肺の病理所見は血管新生によって区別された．この観察結果の普遍性と臨床的意義を明らかにするためにはさらなる研究が必要である．（米国国立衛生研究所ほかから研究助成を受けた．）',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa2015432',\n",
       "  'In our small series, vascular angiogenesis distinguished the pulmonary pathobiology of Covid-19 from that of equally severe influenza virus infection. The universality and clinical implications of our observations require further research to define. (Funded by the National Institutes of Health and others.)'),\n",
       " ('https://nejm.jp/abstract/vol383.p129',\n",
       "  '転倒外傷は，高齢者における合併症と死亡に大きく寄与している．効能に関する試験から，転倒の多くは予防が可能というエビデンスがあるにもかかわらず，外傷にいたる転倒の発生率は低下していない．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa2002183',\n",
       "  'Injuries from falls are major contributors to complications and death in older adults. Despite evidence from efficacy trials that many falls can be prevented, rates of falls resulting in injury have not declined.'),\n",
       " ('https://nejm.jp/abstract/vol383.p129',\n",
       "  '実用的クラスター無作為化試験で，専門の訓練を受けた看護師が実施するリスク評価と個別の計画を含む，転倒外傷を予防するための多因子介入の効果を評価した．10 の医療システムに属するプライマリケア診療所 86 施設を，試験介入と，強化した通常のケア（対照）に無作為に割り付けた（各群 43 施設）．参加者は，転倒外傷のリスクが高い，70 歳以上の地域在住者であった．主要転帰は初回の重篤な転倒外傷とし，参加者による報告，電子診療録，請求データを用いて判定し，生存時間（time-to-event）解析で評価した．イベントの発生率は介入群のほうが対照群よりも 20%低くなるという仮説を立てた．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa2002183',\n",
       "  'We conducted a pragmatic, cluster-randomized trial to evaluate the effectiveness of a multifactorial intervention that included risk assessment and individualized plans, administered by specially trained nurses, to prevent fall injuries. A total of 86 primary care practices across 10 health care systems were randomly assigned to the intervention or to enhanced usual care (the control) (43 practices each). The participants were community-dwelling adults, 70 years of age or older, who were at increased risk for fall injuries. The primary outcome, assessed in a time-to-event analysis, was the first serious fall injury, adjudicated with the use of participant report, electronic health records, and claims data. We hypothesized that the event rate would be lower by 20% in the intervention group than in the control group.'),\n",
       " ('https://nejm.jp/abstract/vol383.p129',\n",
       "  '参加者の人口統計学的特性とベースライン特性は介入群（2,802 例）と対照群（2,649 例）で類似しており，平均年齢は 80 歳で，62.0%が女性であった．生存時間解析による評価では，重篤な転倒外傷と判定された初回イベントの発生率に群間で有意差は認められなかった（追跡期間 100 人年あたりのイベント数は介入群 4.9 件と対照群 5.3 件，ハザード比 0.92，95%信頼区間 [CI] 0.80～1.06，P＝0.25）．参加者が報告した初回転倒外傷の発生率は，介入群で追跡期間 100 人年あたり 25.6 件，対照群で 28.6 件であった（ハザード比 0.90，95% CI 0.83～0.99，P＝0.004）．入院率と死亡率は 2 群で同程度であった．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa2002183',\n",
       "  'The demographic and baseline characteristics of the participants were similar in the intervention group (2802 participants) and the control group (2649 participants); the mean age was 80 years, and 62.0% of the participants were women. The rate of a first adjudicated serious fall injury did not differ significantly between the groups, as assessed in a time-to-first-event analysis (events per 100 person-years of follow-up, 4.9 in the intervention group and 5.3 in the control group; hazard ratio, 0.92; 95% confidence interval [CI], 0.80 to 1.06; P=0.25). The rate of a first participant-reported fall injury was 25.6 events per 100 person-years of follow-up in the intervention group and 28.6 events per 100 person-years of follow-up in the control group (hazard ratio, 0.90; 95% CI, 0.83 to 0.99; P=0.004). The rates of hospitalization or death were similar in the two groups.'),\n",
       " ('https://nejm.jp/abstract/vol383.p129',\n",
       "  '看護師が実施する多因子介入は，強化した通常のケアと比較して，重篤な転倒外傷と判定された初回イベントの発生率を有意には低下させなかった．（患者中心のアウトカム研究所ほかから研究助成を受けた．STRIDE 試験：ClinicalTrials.gov 登録番号 NCT02475850）',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa2002183',\n",
       "  'A multifactorial intervention, administered by nurses, did not result in a significantly lower rate of a first adjudicated serious fall injury than enhanced usual care. (Funded by the Patient-Centered Outcomes Research Institute and others; STRIDE ClinicalTrials.gov number, NCT02475850.)'),\n",
       " ('https://nejm.jp/abstract/vol383.p141',\n",
       "  'ネモリズマブ（nemolizumab）は，アトピー性皮膚炎の瘙痒と炎症に関与するインターロイキン-31 受容体 A に対するヒト化モノクローナル抗体であり，投与は皮下注射で行われる．第 2 相試験で，ネモリズマブはアトピー性皮膚炎の重症度を低下させた．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1917006',\n",
       "  'Nemolizumab is a subcutaneously administered humanized monoclonal antibody against interleukin-31 receptor A, which is involved in pruritus and inflammation in atopic dermatitis. In phase 2 studies, nemolizumab lessened the severity of atopic dermatitis.'),\n",
       " ('https://nejm.jp/abstract/vol383.p141',\n",
       "  '16 週間の二重盲検第 3 相試験で，アトピー性皮膚炎と中等度～重度の瘙痒を有し，外用薬に対する反応が不十分な日本人患者を，外用薬との併用下で，ネモリズマブ（60 mg）を 4 週ごとに 16 週目まで皮下投与する群と，プラセボを投与する群に 2：1 の割合で無作為に割り付けた．主要エンドポイントは，瘙痒ビジュアルアナログスケール（VAS）スコア（0～100 で，スコアが高いほど瘙痒が強いことを示す）のベースラインから 16 週目までの平均変化率とした．副次的エンドポイントは，4 週目までの瘙痒 VAS スコアの変化率の推移，湿疹面積・重症度指数（EASI）スコア（0～72 で，スコアが高いほど重症であることを示す）の変化率，皮膚科 QOL 指数（DLQI）スコア（0～30 で，スコアが高いほど日常生活への影響が大きいことを示す）が 4 以下，不眠重症度指数（ISI）スコア（0～28 で，スコアが高いほど重症であることを示す）が 7 以下，安全性などとした．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1917006',\n",
       "  'In a 16-week, double-blind, phase 3 trial, we randomly assigned Japanese patients with atopic dermatitis and moderate-to-severe pruritus and an inadequate response to topical agents in a 2:1 ratio to receive subcutaneous nemolizumab (60 mg) or placebo every 4 weeks until week 16, with concomitant topical agents. The primary end point was the mean percent change in the visual-analogue scale (VAS) score for pruritus (range, 0 to 100, with higher scores indicating worse pruritus) from baseline to week 16. Secondary end points included the time course of change in the VAS score for pruritus up to week 4, the change in the Eczema Area and Severity Index (EASI) score (range, 0 to 72, with higher scores indicating greater severity), a score of 4 or less on the Dermatology Life Quality Index (DLQI; range, 0 to 30, with higher scores indicating a greater effect on daily life), a score of 7 or less on the Insomnia Severity Index (ISI; range, 0 to 28, with higher scores indicating greater severity), and safety.'),\n",
       " ('https://nejm.jp/abstract/vol383.p141',\n",
       "  '143 例がネモリズマブ群，72 例がプラセボ群に無作為に割り付けられた．ベースラインの瘙痒 VAS スコアの中央値は 75 であった．16 週目の時点で，VAS スコアの平均変化率はネモリズマブ群で －42.8%，プラセボ群で －21.4%であった（差 －21.5 パーセントポイント，95%信頼区間 －30.2～－12.7，P＜0.001）．EASI スコアの平均変化率はネモリズマブ群で －45.9%，プラセボ群で －33.2%であった．DLQI スコアが 4 以下であった患者の割合はネモリズマブ群で 40%，プラセボ群で 22%であり，ISI スコアが 7 以下であった患者の割合はそれぞれ 55%と 21%であった．注射関連反応の発現率はネモリズマブ群で 8%，プラセボ群で 3%であった．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1917006',\n",
       "  'A total of 143 patients were randomly assigned to receive nemolizumab and 72 to receive placebo. The median VAS score for pruritus at baseline was 75. At week 16, the mean percent change in the VAS score was −42.8% in the nemolizumab group and −21.4% in the placebo group (difference, −21.5 percentage points; 95% confidence interval, −30.2 to −12.7; P<0.001). The mean percent change in the EASI score was −45.9% with nemolizumab and −33.2% with placebo. The percentage of patients with a DLQI score of 4 or less was 40% in the nemolizumab group and 22% in the placebo group; the percentage of patients with an ISI score of 7 or less was 55% and 21%, respectively. The incidence of injection-related reactions was 8% with nemolizumab and 3% with placebo.'),\n",
       " ('https://nejm.jp/abstract/vol383.p141',\n",
       "  'この 16 週間の試験では，アトピー性皮膚炎に対し，ネモリズマブの皮下投与を外用薬と併用することで，プラセボ＋外用薬と比較して瘙痒が大きく減少した．注射部位反応の発現率はネモリズマブ群のほうがプラセボ群よりも高かった．アトピー性皮膚炎に対するネモリズマブの効果の持続性と安全性を明らかにするためには，より長期かつ大規模な試験が必要である．（マルホ社から研究助成を受けた．JapicCTI 登録番号 173740）',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1917006',\n",
       "  'In this 16-week trial, the use of subcutaneous nemolizumab in addition to topical agents for atopic dermatitis resulted in a greater reduction in pruritus than placebo plus topical agents. The incidence of injection-site reactions was greater with nemolizumab than with placebo. Longer and larger trials are necessary to determine whether nemolizumab has a durable effect and is safe for atopic dermatitis. (Funded by Maruho; JapicCTI number, 173740.)'),\n",
       " ('https://nejm.jp/abstract/vol383.p207',\n",
       "  '脳梗塞または一過性脳虚血発作（TIA）後の脳卒中の予防に，クロピドグレルとアスピリンの併用がいくつかの試験で評価されている．チカグレロルは，1 件の試験では脳梗塞または TIA 後の血管イベントまたは死亡の予防に関して，アスピリンよりも優れてはいなかった．チカグレロルとアスピリンを併用した場合の脳卒中予防における効果は十分検討されていない．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1916870',\n",
       "  'Trials have evaluated the use of clopidogrel and aspirin to prevent stroke after an ischemic stroke or transient ischemic attack (TIA). In a previous trial, ticagrelor was not better than aspirin in preventing vascular events or death after stroke or TIA. The effect of the combination of ticagrelor and aspirin on prevention of stroke has not been well studied.'),\n",
       " ('https://nejm.jp/abstract/vol383.p207',\n",
       "  '米国国立衛生研究所脳卒中スケール（NIHSS）スコア（0～42 で，スコアが高いほど脳卒中が重症であることを示す）が 5 以下の軽症～中等症の急性期非心原性脳梗塞，または TIA を発症し，血栓溶解療法または血栓除去術が予定されていない患者を対象に無作為化プラセボ対照二重盲検試験を行った．患者を，症状発現後 24 時間以内に，チカグレロル（負荷用量 180 mg，その後は 90 mg を 1 日 2 回）＋アスピリン（1 日目に 300～325 mg，その後は 75～100 mg/日）の 30 日間レジメン，またはマッチさせたプラセボ＋アスピリンの 30 日間レジメンに 1：1 の割合で割り付けた．主要転帰は 30 日以内の脳卒中または死亡の複合とした．副次的転帰は，30 日以内の脳梗塞の初回再発，および障害の発生とした．主要安全性転帰は重度の出血とした．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1916870',\n",
       "  'We conducted a randomized, placebo-controlled, double-blind trial involving patients who had had a mild-to-moderate acute noncardioembolic ischemic stroke, with a National Institutes of Health Stroke Scale (NIHSS) score of 5 or less (range, 0 to 42, with higher scores indicating more severe stroke), or TIA and who were not undergoing thrombolysis or thrombectomy. The patients were assigned within 24 hours after symptom onset, in a 1:1 ratio, to receive a 30-day regimen of either ticagrelor (180-mg loading dose followed by 90 mg twice daily) plus aspirin (300 to 325 mg on the first day followed by 75 to 100 mg daily) or matching placebo plus aspirin. The primary outcome was a composite of stroke or death within 30 days. Secondary outcomes were first subsequent ischemic stroke and the incidence of disability within 30 days. The primary safety outcome was severe bleeding.'),\n",
       " ('https://nejm.jp/abstract/vol383.p207',\n",
       "  '11,016 例が無作為化された（チカグレロル＋アスピリン群 5,523 例，アスピリン群 5,493 例）．主要転帰のイベントはチカグレロル＋アスピリン群の 303 例（5.5%）と，アスピリン群の 362 例（6.6%）に発生した（ハザード比 0.83，95%信頼区間 [CI] 0.71～0.96，P＝0.02）．脳梗塞はチカグレロル＋アスピリン群の 276 例（5.0%）と，アスピリン群の 345 例（6.3%）に発生した（ハザード比 0.79，95% CI 0.68～0.93，P＝0.004）．障害の発生に 2 群間で有意差は認められなかった．重度の出血はチカグレロル＋アスピリン群の 28 例（0.5%）と，アスピリン群の 7 例（0.1%）に発生した（P＝0.001）．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1916870',\n",
       "  'A total of 11,016 patients underwent randomization (5523 in the ticagrelor–aspirin group and 5493 in the aspirin group). A primary-outcome event occurred in 303 patients (5.5%) in the ticagrelor–aspirin group and in 362 patients (6.6%) in the aspirin group (hazard ratio, 0.83; 95% confidence interval [CI], 0.71 to 0.96; P=0.02). Ischemic stroke occurred in 276 patients (5.0%) in the ticagrelor–aspirin group and in 345 patients (6.3%) in the aspirin group (hazard ratio, 0.79; 95% CI, 0.68 to 0.93; P=0.004). The incidence of disability did not differ significantly between the two groups. Severe bleeding occurred in 28 patients (0.5%) in the ticagrelor–aspirin group and in 7 patients (0.1%) in the aspirin group (P=0.001).'),\n",
       " ('https://nejm.jp/abstract/vol383.p207',\n",
       "  '軽症～中等症（NIHSS スコア 5 以下）の急性期非心原性脳梗塞または TIA を発症し，静脈内・動脈内血栓溶解療法または血栓除去術が予定されていない患者では，30 日以内の脳卒中または死亡の複合転帰のリスクは，チカグレロル＋アスピリン群のほうがアスピリン単独群よりも低かったが，障害の発生に 2 群間で有意差は認められなかった．重度の出血の頻度はチカグレロル群のほうが高かった．（アストラゼネカ社から研究助成を受けた．THALES 試験：ClinicalTrials.gov 登録番号 NCT03354429）',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1916870',\n",
       "  'Among patients with a mild-to-moderate acute noncardioembolic ischemic stroke (NIHSS score ≤5) or TIA who were not undergoing intravenous or endovascular thrombolysis, the risk of the composite of stroke or death within 30 days was lower with ticagrelor–aspirin than with aspirin alone, but the incidence of disability did not differ significantly between the two groups. Severe bleeding was more frequent with ticagrelor. (Funded by AstraZeneca; THALES ClinicalTrial.gov number, NCT03354429.)'),\n",
       " ('https://nejm.jp/abstract/vol383.p218',\n",
       "  '関節リウマチは，多くの炎症性疾患と同様，寛解と増悪（再燃）を繰り返すことを特徴とする．再燃につながる分子イベントは明らかにされていない．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa2004114',\n",
       "  'Rheumatoid arthritis, like many inflammatory diseases, is characterized by episodes of quiescence and exacerbation (flares). The molecular events leading to flares are unknown.'),\n",
       " ('https://nejm.jp/abstract/vol383.p218',\n",
       "  '関節リウマチ患者の経時的な RNA 配列解析（RNA-seq）を可能とする，自宅で繰り返し採血するための臨床的・技術的プロトコルを確立した．検体は，指標とした 1 例では 4 年間で 8 回の再燃中の 364 時点，別の 3 例では再燃中の 235 時点で採取された．再燃前に発現に違いが認められた転写産物を同定し，滑膜の 1 細胞 RNA-seq のデータと比較した．得られた知見の妥当性を検証するため，別の患者で，フローサイトメトリーで選別した血液細胞の RNA-seq を行った．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa2004114',\n",
       "  'We established a clinical and technical protocol for repeated home collection of blood in patients with rheumatoid arthritis to allow for longitudinal RNA sequencing (RNA-seq). Specimens were obtained from 364 time points during eight flares over a period of 4 years in our index patient, as well as from 235 time points during flares in three additional patients. We identified transcripts that were differentially expressed before flares and compared these with data from synovial single-cell RNA-seq. Flow cytometry and sorted-blood-cell RNA-seq in additional patients were used to validate the findings.'),\n",
       " ('https://nejm.jp/abstract/vol383.p218',\n",
       "  '関節リウマチの再燃前の 1～2 週間に，血液の転写プロファイルに一貫した変化が観察された．関節リウマチ患者の血液中では，B 細胞の活性化後，循環する CD45–CD31–PDPN＋の前炎症性間葉（PRIME）細胞が増加した．これらの細胞の特徴は，炎症性滑膜線維芽細胞と共通していた．循環血中の PRIME 細胞は，4 例全例で再燃中に減少し，別の 19 例の関節リウマチ患者では，フローサイトメトリーで選別した細胞の RNA-seq によって PRIME 細胞の存在が確認された．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa2004114',\n",
       "  'Consistent changes were observed in blood transcriptional profiles 1 to 2 weeks before a rheumatoid arthritis flare. B-cell activation was followed by expansion of circulating CD45−CD31−PDPN+ preinflammatory mesenchymal, or PRIME, cells in the blood from patients with rheumatoid arthritis; these cells shared features of inflammatory synovial fibroblasts. Levels of circulating PRIME cells decreased during flares in all 4 patients, and flow cytometry and sorted-cell RNA-seq confirmed the presence of PRIME cells in 19 additional patients with rheumatoid arthritis.'),\n",
       " ('https://nejm.jp/abstract/vol383.p218',\n",
       "  '関節リウマチの再燃の経時的なゲノム解析により，再燃前の時期には血中に PRIME 細胞が存在することが明らかになり，これらの細胞は再燃前の数週間に B 細胞によって活性化され，その後血中から滑膜に移動するというモデルが示唆された．（米国国立衛生研究所ほかから研究助成を受けた．）',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa2004114',\n",
       "  'Longitudinal genomic analysis of rheumatoid arthritis flares revealed PRIME cells in the blood during the period before a flare and suggested a model in which these cells become activated by B cells in the weeks before a flare and subsequently migrate out of the blood into the synovium. (Funded by the National Institutes of Health and others.)'),\n",
       " ('https://nejm.jp/abstract/vol383.p229',\n",
       "  '全身性の経口ホスホジエステラーゼ 4（PDE-4）阻害薬は，乾癬の治療に有効であることが示されている．PDE-4 阻害薬を含有するロフルミラスト（roflumilast）クリームは，乾癬の外用治療薬として検討されている．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa2000073',\n",
       "  'Systemic oral phosphodiesterase type 4 (PDE-4) inhibitors have been effective in the treatment of psoriasis. Roflumilast cream contains a PDE-4 inhibitor that is being investigated for the topical treatment of psoriasis.'),\n",
       " ('https://nejm.jp/abstract/vol383.p229',\n",
       "  '第 2b 相二重盲検試験で，尋常性乾癬の成人を，ロフルミラスト 0.3%クリーム，ロフルミラスト 0.15%クリーム，基剤のみの（プラセボ）クリームのいずれかを 1 日 1 回 12 週間使用する 3 群に，1：1：1 の割合で無作為に割り付けた．主要有効性評価項目は，6 週の時点での医師による全般的評価（IGA；乾癬部位の肥厚，鱗屑，紅斑を 5 段階で評価し，0 は消失，1 はほぼ消失，4 は重症を示す）で，皮疹の消失またはほぼ消失の状態とした．副次的評価項目は，皮疹の消失またはほぼ消失を示す IGA スコア＋間擦部の IGA スコアの 2 段階の改善や，乾癬の面積・重症度指数（PASI）スコア（0～72 で，スコアが高いほど重症であることを示す）の変化などとした．安全性も評価した．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa2000073',\n",
       "  'In this phase 2b, double-blind trial, we randomly assigned adults with plaque psoriasis in a 1:1:1 ratio to use roflumilast 0.3% cream, roflumilast 0.15% cream, or vehicle (placebo) cream once daily for 12 weeks. The primary efficacy outcome was the investigator’s global assessment (IGA) of a status of clear or almost clear at week 6 (assessed on a 5-point scale of plaque thickening, scaling, and erythema; a score of 0 indicates clear, 1 almost clear, and 4 severe). Secondary outcomes included an IGA score indicating clear or almost clear plus a 2-grade improvement in the IGA score for the intertriginous area and the change in the Psoriasis Area and Severity Index (PASI) score (range, 0 to 72, with higher scores indicating worse disease). Safety was also assessed.'),\n",
       " ('https://nejm.jp/abstract/vol383.p229',\n",
       "  '無作為化された 331 例のうち，109 例がロフルミラスト 0.3%クリーム，113 例がロフルミラスト 0.15%クリーム，109 例が基剤のみのクリームに割り付けられた．6 週の時点での皮疹の消失またはほぼ消失を示す IGA スコアは，ロフルミラスト 0.3%群の 28%，ロフルミラスト 0.15%群の 23%，基剤群の 8%で認められた（基剤に対し，ロフルミラスト 0.3%は P＜0.001，ロフルミラスト 0.15%は P＝0.004）．全体の約 15%に相当する，ベースライン時の間擦部の皮疹が軽度以上であった患者では，6 週の時点で皮疹の消失またはほぼ消失を示す IGA スコア＋間擦部の IGA スコアの 2 段階の改善が認められたのは，ロフルミラスト 0.3%群の 73%，ロフルミラスト 0.15%群の 44%，基剤群の 29%であった．ベースラインの PASI スコアの平均は，ロフルミラスト 0.3%群 7.7 点，ロフルミラスト 0.15%群 8.0 点，基剤群 7.6 点であり，6 週の時点でのベースラインからの変化の平均は，それぞれ －50.0%，－49.0%，－17.8%であった．塗布部位反応の発現頻度は，ロフルミラストの 2 群と基剤群で同程度であった．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa2000073',\n",
       "  'Among 331 patients who underwent randomization, 109 were assigned to roflumilast 0.3% cream, 113 to roflumilast 0.15% cream, and 109 to vehicle cream. An IGA score indicating clear or almost clear at week 6 was observed in 28% of the patients in the roflumilast 0.3% group, in 23% in the roflumilast 0.15% group, and in 8% in the vehicle group (P<0.001 and P=0.004 vs. vehicle for roflumilast 0.3% and 0.15%, respectively). Among the approximately 15% of patients overall who had baseline intertriginous psoriasis of at least mild severity, an IGA score at week 6 indicating clear or almost clear plus a 2-grade improvement in the intertriginous-area IGA score occurred in 73% of the patients in the roflumilast 0.3% group, 44% of those in the roflumilast 0.15% group, and 29% of those in the vehicle group. The mean baseline PASI scores were 7.7 in the roflumilast 0.3% group, 8.0 in the roflumilast 0.15% group, and 7.6 in the vehicle group; the mean change from baseline at week 6 was −50.0%, −49.0%, and −17.8%, respectively. Application-site reactions occurred with similar frequency in the roflumilast groups and the vehicle group.'),\n",
       " ('https://nejm.jp/abstract/vol383.p229',\n",
       "  '乾癬の患部に 1 日 1 回塗布するロフルミラストクリームは，6 週の時点で皮疹が消失またはほぼ消失した状態になる点で，基剤のみのクリームよりも優れていた．乾癬に対するロフルミラストの効果の持続性と安全性を明らかにするには，より長期かつ大規模な試験が必要である．（Arcutis Biotherapeutics 社から研究助成を受けた．ARQ-151 201 試験：ClinicalTrials.gov 登録番号 NCT03638258）',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa2000073',\n",
       "  'Roflumilast cream administered once daily to affected areas of psoriasis was superior to vehicle cream in leading to a state of clear or almost clear at 6 weeks. Longer and larger trials are needed to determine the durability and safety of roflumilast in psoriasis. (Funded by Arcutis Biotherapeutics; ARQ-151 201 ClinicalTrials.gov number, NCT03638258.)'),\n",
       " ('https://nejm.jp/abstract/vol383.p240',\n",
       "  '急性腎障害（AKI）は重症患者によくみられ，その多くは腎代替療法を受ける．しかし，腎代替療法の開始にもっとも有効な時期は明らかにされていない．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa2000741',\n",
       "  'Acute kidney injury is common in critically ill patients, many of whom receive renal-replacement therapy. However, the most effective timing for the initiation of such therapy remains uncertain.'),\n",
       " ('https://nejm.jp/abstract/vol383.p240',\n",
       "  '重度の AKI を生じた重症患者を対象に，多国間無作為化比較試験を行った．患者を，腎代替療法の早期開始戦略（患者が適格基準を満たしてから 12 時間以内に腎代替療法を開始する）群と，標準戦略（従来の適応症が出現するか，AKI の持続時間が 72 時間を超えるまで腎代替療法は見合わせる）群に無作為に割り付けた．主要転帰は 90 日の時点での全死因死亡とした．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa2000741',\n",
       "  'We conducted a multinational, randomized, controlled trial involving critically ill patients with severe acute kidney injury. Patients were randomly assigned to receive an accelerated strategy of renal-replacement therapy (in which therapy was initiated within 12 hours after the patient had met eligibility criteria) or a standard strategy (in which renal-replacement therapy was discouraged unless conventional indications developed or acute kidney injury persisted for >72 hours). The primary outcome was death from any cause at 90 days.'),\n",
       " ('https://nejm.jp/abstract/vol383.p240',\n",
       "  '無作為化された 3,019 例のうち，2,927 例（97.0%）を修正 intention-to-treat 解析の対象とした（早期開始戦略群 1,465 例，標準戦略群 1,462 例）．このうち，早期開始戦略群の 1,418 例（96.8%）と標準戦略群の 903 例（61.8%）で腎代替療法が施行された．90 日の時点で，死亡は早期開始戦略群の 643 例（43.9%）と標準戦略群の 639 例（43.7%）で発生した（相対リスク 1.00，95%信頼区間 [CI] 0.93～1.09，P＝0.92）．90 日の時点で生存していた患者のうち，腎代替療法の必要性は，早期開始戦略群の 814 例中 85 例（10.4%）と標準戦略群の 815 例中 49 例（6.0%）で継続していることが確認された（相対リスク 1.74，95% CI 1.24～2.43）．有害事象は，早期開始戦略群の 1,503 例中 346 例（23.0%）と標準戦略群の 1,489 例中 245 例（16.5%）に発現した（P＜0.001）．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa2000741',\n",
       "  'Of the 3019 patients who had undergone randomization, 2927 (97.0%) were included in the modified intention-to-treat analysis (1465 in the accelerated-strategy group and 1462 in the standard-strategy group). Of these patients, renal-replacement therapy was performed in 1418 (96.8%) in the accelerated-strategy group and in 903 (61.8%) in the standard-strategy group. At 90 days, death had occurred in 643 patients (43.9%) in the accelerated-strategy group and in 639 (43.7%) in the standard-strategy group (relative risk, 1.00; 95% confidence interval [CI], 0.93 to 1.09; P=0.92). Among survivors at 90 days, continued dependence on renal-replacement therapy was confirmed in 85 of 814 patients (10.4%) in the accelerated-strategy group and in 49 of 815 patients (6.0%) in the standard-strategy group (relative risk, 1.74; 95% CI, 1.24 to 2.43). Adverse events occurred in 346 of 1503 patients (23.0%) in the accelerated-strategy group and in 245 of 1489 patients (16.5%) in the standard-strategy group (P<0.001).'),\n",
       " ('https://nejm.jp/abstract/vol383.p240',\n",
       "  'AKI を生じた重症患者では，腎代替療法を早期に開始する戦略をとっても，標準戦略をとった場合と比較して 90 日の時点での死亡リスクが低いことには関連しなかった．（カナダ国立保健研究機構ほかから研究助成を受けた．STARRT-AKI 試験：ClinicalTrials.gov 登録番号 NCT02568722）',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa2000741',\n",
       "  'Among critically ill patients with acute kidney injury, an accelerated renal-replacement strategy was not associated with a lower risk of death at 90 days than a standard strategy. (Funded by the Canadian Institutes of Health Research and others; STARRT-AKI ClinicalTrials.gov number, NCT02568722.)'),\n",
       " ('https://nejm.jp/abstract/vol383.p309',\n",
       "  'バロキサビル マルボキシル（バロキサビル）は，ポリメラーゼ酸性蛋白（PA）エンドヌクレアーゼ阻害薬であり，一般の外来患者ならびに合併症リスクの高い患者のインフルエンザ治療に臨床的に有用であることが示されている．しかし，バロキサビルの家庭内でのインフルエンザの曝露後感染予防効果は明らかにされていない．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1915341',\n",
       "  'Baloxavir marboxil (baloxavir) is a polymerase acidic protein (PA) endonuclease inhibitor with clinical efficacy in the treatment of uncomplicated influenza, including in outpatients at increased risk for complications. The postexposure prophylactic efficacy of baloxavir in the household setting is unclear.'),\n",
       " ('https://nejm.jp/abstract/vol383.p309',\n",
       "  '日本の 2018～19 年インフルエンザ流行期に，インフルエンザが確定した発端患者の同居家族を対象に，バロキサビルの曝露後予防効果を評価する多施設共同二重盲検無作為化プラセボ対照試験を行った．参加者を，バロキサビル単回投与群とプラセボ群に 1：1 の割合で割り付けた．主要エンドポイントは，10 日間の観察期間中に逆転写ポリメラーゼ連鎖反応（RT-PCR）検査で確定した臨床的なインフルエンザの発症とした．バロキサビル投与後に出現した PA 変異ウイルスでの薬剤感受性低下が示されており，対象者における PA 変異ウイルスの出現についても評価した．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1915341',\n",
       "  'We conducted a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the postexposure prophylactic efficacy of baloxavir in household contacts of index patients with confirmed influenza during the 2018–2019 season in Japan. The participants were assigned in a 1:1 ratio to receive either a single dose of baloxavir or placebo. The primary end point was clinical influenza, as confirmed by reverse-transcriptase–polymerase-chain-reaction testing, over a period of 10 days. The occurrence of baloxavir-selected PA substitutions associated with reduced susceptibility was assessed.'),\n",
       " ('https://nejm.jp/abstract/vol383.p309',\n",
       "  '発端患者 545 例の同居家族 752 例が，バロキサビル単回投与またはプラセボ投与に無作為に割り付けられた．発端患者は，95.6%が A 型インフルエンザで，73.6%が 12 歳未満，52.7%がバロキサビルで治療された．解析対象者（バロキサビル群 374 例，プラセボ群 375 例）のうち，RT-PCR 検査で確定した臨床的なインフルエンザを発症した割合は，バロキサビル群のほうがプラセボ群よりも有意に低かった（1.9% 対 13.6%）（補正リスク比 0.14，95%信頼区間 [CI] 0.06～0.30，P＜0.001）．サブグループ解析で，バロキサビルは，高リスク者，小児，ワクチン未接種者でも予防に有効であった．症状の有無にかかわらず RT-PCR 検査で確認されたインフルエンザウイルスの感染率は，バロキサビル群のほうがプラセボ群よりも低かった（補正リスク比 0.43，95% CI 0.32～0.58）．有害事象の発現率は 2 群で同程度であった（バロキサビル群 22.2%，プラセボ群 20.5%）．バロキサビル群 374 例で，PA の I38T/M 変異ウイルスが 10 例（2.7%），E23K 変異ウイルスが 5 例（1.3%）で検出された．バロキサビルの投与を受けた発端患者からの変異ウイルスの伝播は，プラセボ群では認められなかったが，バロキサビル群の一部ではその伝播を否定できなかった．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1915341',\n",
       "  'A total of 752 household contacts of 545 index patients were randomly assigned to receive baloxavir or placebo. Among the index patients, 95.6% had influenza A virus infection, 73.6% were younger than 12 years of age, and 52.7% received baloxavir. Among the participants who could be evaluated (374 in the baloxavir group and 375 in the placebo group), the percentage in whom clinical influenza developed was significantly lower in the baloxavir group than in the placebo group (1.9% vs. 13.6%) (adjusted risk ratio, 0.14; 95% confidence interval [CI], 0.06 to 0.30; P<0.001). Baloxavir was effective in high-risk, pediatric, and unvaccinated subgroups of participants. The risk of influenza infection, regardless of symptoms, was lower with baloxavir than with placebo (adjusted risk ratio, 0.43; 95% CI, 0.32 to 0.58). The incidence of adverse events was similar in the two groups (22.2% in the baloxavir group and 20.5% in the placebo group). In the baloxavir group, the viral PA substitutions I38T/M or E23K were detected in 10 (2.7%) and 5 (1.3%) participants, respectively. No transmission of these variants from baloxavir-treated index patients to participants in the placebo group was detected; however, several instances of transmission to participants in the baloxavir group could not be ruled out.'),\n",
       " ('https://nejm.jp/abstract/vol383.p309',\n",
       "  'バロキサビルの単回投与は，インフルエンザの家庭内での感染において，有意な曝露後の予防効果を示した．（この臨床試験は塩野義製薬から支援を受けた．ジャパン・プライマリ・レジストリーズ・ネットワーク登録番号：JapicCTI-184180）',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1915341',\n",
       "  'Single-dose baloxavir showed significant postexposure prophylactic efficacy in preventing influenza in household contacts of patients with influenza. (Funded by Shionogi; Japan Primary Registries Network number, JapicCTI-184180.)'),\n",
       " ('https://nejm.jp/abstract/vol383.p321',\n",
       "  '環境腸管機能障害（EED）は，小児期の低栄養に関与すると推定される謎の小腸疾患であり，差し迫ったグローバルヘルス問題である．小腸粘膜と微生物群集（微生物叢）を直接採取することは困難であるため，この疾患の発生率，病態生理学的特徴，低身長・体重増加不良への寄与を明らかにできずにいる．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1916004',\n",
       "  'Environmental enteric dysfunction (EED) is an enigmatic disorder of the small intestine that is postulated to play a role in childhood undernutrition, a pressing global health problem. Defining the incidence of this disorder, its pathophysiological features, and its contribution to impaired linear and ponderal growth has been hampered by the difficulty in directly sampling the small intestinal mucosa and microbial community (microbiota).'),\n",
       " ('https://nejm.jp/abstract/vol383.p321',\n",
       "  'この研究では，バングラデシュ・ダッカの都市部のスラムに居住し，栄養介入による利益が得られていない低身長の幼児 110 例（平均月齢 18 ヵ月）のうち，生検で EED が確認され，血漿と十二指腸の検体が得られた 80 例に内視鏡検査を行った．これらの幼児から得た血漿中の 4,077 種類の蛋白と十二指腸生検検体中の 2,619 種類の蛋白を定量した．各児の十二指腸吸引物から回収した微生物叢に含まれる菌株の量を，培養に依存しない手法を用いて決定した．さらに，同じ地域に居住する，年齢をマッチさせた健康な幼児から 21 の血漿検体と 27 の便検体を採取した．バングラデシュ食を与えた無菌幼若マウスに，幼児の十二指腸吸引物から培養した菌株を定着させた．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1916004',\n",
       "  'In this study, among 110 young children (mean age, 18 months) with linear growth stunting who were living in an urban slum in Dhaka, Bangladesh, and had not benefited from a nutritional intervention, we performed endoscopy in 80 children who had biopsy-confirmed EED and available plasma and duodenal samples. We quantified the levels of 4077 plasma proteins and 2619 proteins in duodenal biopsy samples obtained from these children. The levels of bacterial strains in microbiota recovered from duodenal aspirate from each child were determined with the use of culture-independent methods. In addition, we obtained 21 plasma samples and 27 fecal samples from age-matched healthy children living in the same area. Young germ-free mice that had been fed a Bangladeshi diet were colonized with bacterial strains cultured from the duodenal aspirates.'),\n",
       " ('https://nejm.jp/abstract/vol383.p321',\n",
       "  '幼児から得た菌株のうち，共通する 14 の細菌分類群（通常，腸管病原体には分類されない）の絶対値は，身長の伸びと負の相関を示し（年齢に対する身長の z スコア：r＝－0.49，P＝0.003），免疫炎症反応に関与する十二指腸の蛋白と正の相関を示した．糞便微生物叢中に含まれるこれらの 14 の十二指腸細菌分類群の組成は，健康な幼児から得た検体の組成と大きく異なっていた（置換分散多変量解析 [PERMANOVA] で P＜0.001）．EED を有する児の十二指腸培養株を定着させたノトバイオートマウスでは，小腸に疾患が発生した．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1916004',\n",
       "  'Of the bacterial strains that were obtained from the children, the absolute levels of a shared group of 14 taxa (which are not typically classified as enteropathogens) were negatively correlated with linear growth (length-for-age z score, r=−0.49; P=0.003) and positively correlated with duodenal proteins involved in immunoinflammatory responses. The representation of these 14 duodenal taxa in fecal microbiota was significantly different from that in samples obtained from healthy children (P<0.001 by permutational multivariate analysis of variance). Enteropathy of the small intestine developed in gnotobiotic mice that had been colonized with cultured duodenal strains obtained from children with EED.'),\n",
       " ('https://nejm.jp/abstract/vol383.p321',\n",
       "  'これらの結果は，発育障害と小腸微生物叢の構成および腸疾患との因果関係を支持し，これらの微生物の EED への関与を標的とする治療法を開発するための合理的根拠を提供している．（ビル&メリンダ・ゲイツ財団ほかから研究助成を受けた．ClinicalTrials.gov 登録番号 NCT02812615）',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1916004',\n",
       "  'These results provide support for a causal relationship between growth stunting and components of the small intestinal microbiota and enteropathy and offer a rationale for developing therapies that target these microbial contributions to EED. (Funded by the Bill and Melinda Gates Foundation and others; ClinicalTrials.gov number, NCT02812615.)'),\n",
       " ('https://nejm.jp/abstract/vol383.p334',\n",
       "  '小児多臓器炎症症候群（MIS-C）の疫学と臨床経過，および新型コロナウイルス感染症（Covid-19）との時間的関連を理解することは，この症候群が臨床と公衆衛生に及ぼす影響を考慮すると重要である．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa2021680',\n",
       "  'Understanding the epidemiology and clinical course of multisystem inflammatory syndrome in children (MIS-C) and its temporal association with coronavirus disease 2019 (Covid-19) is important, given the clinical and public health implications of the syndrome.'),\n",
       " ('https://nejm.jp/abstract/vol383.p334',\n",
       "  '米国内の小児病院で，MIS-C を対象としたサーベイランスを 2020 年 3 月 15 日～5 月 20 日に行った．症例の定義には，入院にいたる重症化，年齢 21 歳未満，24 時間以上続く発熱，炎症の臨床検査所見，多臓器症状，重症急性呼吸器症候群コロナウイルス 2（SARS-CoV-2）感染の証拠という 6 つの基準が含まれた．SARS-CoV-2 感染の証拠は，逆転写ポリメラーゼ連鎖反応（RT-PCR）陽性，抗体検査陽性，または過去 1 ヵ月以内の Covid-19 患者への曝露とした．臨床家がデータを標準化されたフォームにまとめた．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa2021680',\n",
       "  'We conducted targeted surveillance for MIS-C from March 15 to May 20, 2020, in pediatric health centers across the United States. The case definition included six criteria: serious illness leading to hospitalization, an age of less than 21 years, fever that lasted for at least 24 hours, laboratory evidence of inflammation, multisystem organ involvement, and evidence of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) based on reverse-transcriptase polymerase chain reaction (RT-PCR), antibody testing, or exposure to persons with Covid-19 in the past month. Clinicians abstracted the data onto standardized forms.'),\n",
       " ('https://nejm.jp/abstract/vol383.p334',\n",
       "  '26 州の MIS-C 患児 186 例について報告する．年齢の中央値は 8.3 歳，115 例（62%）は男性で，135 例（73%）は生来健康であり，131 例（70%）が RT-PCR または抗体検査で SARS-CoV-2 陽性，164 例（88%）が 2020 年 4 月 16 日以降に入院した．臓器系の症状は，消化器 171 例（92%），循環器 149 例（80%），血液 142 例（76%），皮膚粘膜 137 例（74%），呼吸器 131 例（70%）であった．入院期間の中央値は 7 日（四分位範囲 4～10）で，148 例（80%）が集中治療，37 例（20%）が人工呼吸管理，90 例（48%）が血管作動薬による補助を受け，4 例（2%）が死亡した．冠動脈瘤（z スコア 2.5 以上）が 15 例（8%）に認められ，川崎病様の症状が 74 例（40%）に認められた．ほとんどの患者（171 例 [92%]）で，炎症を示すバイオマーカーが 4 つ以上上昇していた．免疫調節療法が用いられることが多く，144 例（77%）に免疫グロブリン静注，91 例（49%）にグルココルチコイド，38 例（20%）にインターロイキン-6 阻害薬またはインターロイキン-1RA 阻害薬の投与が行われた．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa2021680',\n",
       "  'We report on 186 patients with MIS-C in 26 states. The median age was 8.3 years, 115 patients (62%) were male, 135 (73%) had previously been healthy, 131 (70%) were positive for SARS-CoV-2 by RT-PCR or antibody testing, and 164 (88%) were hospitalized after April 16, 2020. Organ-system involvement included the gastrointestinal system in 171 patients (92%), cardiovascular in 149 (80%), hematologic in 142 (76%), mucocutaneous in 137 (74%), and respiratory in 131 (70%). The median duration of hospitalization was 7 days (interquartile range, 4 to 10); 148 patients (80%) received intensive care, 37 (20%) received mechanical ventilation, 90 (48%) received vasoactive support, and 4 (2%) died. Coronary-artery aneurysms (z scores ≥2.5) were documented in 15 patients (8%), and Kawasaki’s disease–like features were documented in 74 (40%). Most patients (171 [92%]) had elevations in at least four biomarkers indicating inflammation. The use of immunomodulating therapies was common: intravenous immune globulin was used in 144 (77%), glucocorticoids in 91 (49%), and interleukin-6 or 1RA inhibitors in 38 (20%).'),\n",
       " ('https://nejm.jp/abstract/vol383.p334',\n",
       "  '小児における SARS-CoV-2 に関連した多臓器炎症症候群は，生来健康であった小児・青年において重篤化し，生命を脅かした．（米国疾病対策予防センターから研究助成を受けた．）',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa2021680',\n",
       "  'Multisystem inflammatory syndrome in children associated with SARS-CoV-2 led to serious and life-threatening illness in previously healthy children and adolescents. (Funded by the Centers for Disease Control and Prevention.)'),\n",
       " ('https://nejm.jp/abstract/vol383.p347',\n",
       "  '小児における多臓器炎症症候群（MIS-C）は新型コロナウイルス感染症と関連している．ニューヨーク州保健局（NYSDOH）は，MIS-C で入院した患児について，全州規模の積極的サーベイランスを確立した．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa2021756',\n",
       "  'A multisystem inflammatory syndrome in children (MIS-C) is associated with coronavirus disease 2019. The New York State Department of Health (NYSDOH) established active, statewide surveillance to describe hospitalized patients with the syndrome.'),\n",
       " ('https://nejm.jp/abstract/vol383.p347',\n",
       "  'ニューヨーク州の病院が，21 歳未満の入院患児における川崎病，トキシックショック症候群，心筋炎の症例，MIS-C の可能性がある症例を NYSDOH に報告し，診療録を送付した．記述的分析を行い，2020 年 3 月 1 日～5 月 10 日に NYSDOH の MIS-C の症例定義を満たした患児の臨床像，合併症，転帰を要約した．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa2021756',\n",
       "  'Hospitals in New York State reported cases of Kawasaki’s disease, toxic shock syndrome, myocarditis, and potential MIS-C in hospitalized patients younger than 21 years of age and sent medical records to the NYSDOH. We carried out descriptive analyses that summarized the clinical presentation, complications, and outcomes of patients who met the NYSDOH case definition for MIS-C between March 1 and May 10, 2020.'),\n",
       " ('https://nejm.jp/abstract/vol383.p347',\n",
       "  '2020 年 5 月 10 日の時点で，MIS-C の可能性がある症例 191 例が NYSDOH に報告された．MIS-C の確診例 95 例（検査で確認された急性または最近の重症急性呼吸器症候群コロナウイルス 2 [SARS-CoV-2] 感染）と疑い例 4 例（臨床基準と疫学的基準を満たした）のうち，53 例（54%）が男性で，人種に関するデータのあった 78 例中 31 例（40%）が黒人，民族に関するデータのあった 85 例中 31 例（36%）がヒスパニック系であった．31 例（31%）が 0～5 歳，42 例（42%）が 6～12 歳，26 例（26%）が 13～20 歳であった．全例が自覚的な熱感または悪寒を訴えて受診しており，97%に頻脈，80%に消化器症状，60%に皮疹，56%に結膜充血，27%に粘膜の変化が認められた．C 反応性蛋白値，D ダイマー値，トロポニン値の上昇が，それぞれ患児の 100%，91%，71%に認められた．62%が昇圧薬による補助療法を受け，53%に心筋炎の所見があり，80%が集中治療室に入室し，2 例が死亡した．入院期間の中央値は 6 日であった．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa2021756',\n",
       "  'As of May 10, 2020, a total of 191 potential cases were reported to the NYSDOH. Of 95 patients with confirmed MIS-C (laboratory-confirmed acute or recent severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] infection) and 4 with suspected MIS-C (met clinical and epidemiologic criteria), 53 (54%) were male; 31 of 78 (40%) were black, and 31 of 85 (36%) were Hispanic. A total of 31 patients (31%) were 0 to 5 years of age, 42 (42%) were 6 to 12 years of age, and 26 (26%) were 13 to 20 years of age. All presented with subjective fever or chills; 97% had tachycardia, 80% had gastrointestinal symptoms, 60% had rash, 56% had conjunctival injection, and 27% had mucosal changes. Elevated levels of C-reactive protein, d-dimer, and troponin were found in 100%, 91%, and 71% of the patients, respectively; 62% received vasopressor support, 53% had evidence of myocarditis, 80% were admitted to an intensive care unit, and 2 died. The median length of hospital stay was 6 days.'),\n",
       " ('https://nejm.jp/abstract/vol383.p347',\n",
       "  'ニューヨーク州の小児における多臓器炎症症候群の出現は，SARS-CoV-2 の感染拡大と同じ時期にみられた．皮膚，皮膚粘膜，消化器の症状を伴うこの過剰炎症症候群は，心機能障害と関連していた．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa2021756',\n",
       "  'The emergence of multisystem inflammatory syndrome in children in New York State coincided with widespread SARS-CoV-2 transmission; this hyperinflammatory syndrome with dermatologic, mucocutaneous, and gastrointestinal manifestations was associated with cardiac dysfunction.'),\n",
       " ('https://nejm.jp/abstract/vol383.p359',\n",
       "  'ビタミン D 代謝物は結核菌（Mycobacterium tuberculosis）に対する自然免疫応答を補助している．結核感染予防を目的としたビタミン D 補充の第 3 相無作為化比較試験のデータは不足している．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1915176',\n",
       "  'Vitamin D metabolites support innate immune responses to Mycobacterium tuberculosis. Data from phase 3, randomized, controlled trials of vitamin D supplementation to prevent tuberculosis infection are lacking.'),\n",
       " ('https://nejm.jp/abstract/vol383.p359',\n",
       "  'QuantiFERON-TB Gold In-tube アッセイ（QFT）で結核菌が陰性であった小児を，ビタミン D3 14,000 IU を週 1 回 3 年間経口摂取する群とプラセボを摂取する群に無作為に割り付けた．主要転帰は追跡 3 年の時点での QFT 陽性とし，陽性者の割合で表した．副次的転帰は，試験終了時の血清 25-ヒドロキシビタミン D（25 [OH] D）濃度，結核症，急性呼吸器感染症，有害事象の発生率などとした．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1915176',\n",
       "  'We randomly assigned children who had negative results for M. tuberculosis infection according to the QuantiFERON-TB Gold In-Tube assay (QFT) to receive a weekly oral dose of either 14,000 IU of vitamin D3 or placebo for 3 years. The primary outcome was a positive QFT result at the 3-year follow-up, expressed as a proportion of children. Secondary outcomes included the serum 25-hydroxyvitamin D (25[OH]D) level at the end of the trial and the incidence of tuberculosis disease, acute respiratory infection, and adverse events.'),\n",
       " ('https://nejm.jp/abstract/vol383.p359',\n",
       "  '8,851 例が無作為化され，4,418 例がビタミン D 群，4,433 例がプラセボ群に割り付けられた．小児の 95.6%はベースラインの血清 25（OH）D 濃度が 20 ng/mL 未満であった．試験終了時に，QFT で妥当な結果が得られた小児のうち陽性であった割合は，ビタミン D 群で 3.6%（4,074 例中 147 例），プラセボ群で 3.3%（4,043 例中 134 例）であった（補正リスク比 1.10，95%信頼区間 [CI] 0.87～1.38，P＝0.42）．試験終了時の 25（OH）D 濃度の平均値はビタミン D 群で 31.0 ng/mL，プラセボ群で 10.7 ng/mL であった（平均値の群間差 20.3 ng/mL，95% CI 19.9～20.6）．結核症はビタミン D 群の 21 例とプラセボ群の 25 例で診断された（補正リスク比 0.87，95% CI 0.49～1.55）．ビタミン D 群の 29 例とプラセボ群の 34 例が急性呼吸器感染症の治療のため入院した（補正リスク比 0.86，95% CI 0.52～1.40）．有害事象の発現率に 2 群間で有意差は認められなかった．',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1915176',\n",
       "  'A total of 8851 children underwent randomization: 4418 were assigned to the vitamin D group, and 4433 to the placebo group; 95.6% of children had a baseline serum 25(OH)D level of less than 20 ng per milliliter. Among children with a valid QFT result at the end of the trial, the percentage with a positive result was 3.6% (147 of 4074 children) in the vitamin D group and 3.3% (134 of 4043) in the placebo group (adjusted risk ratio, 1.10; 95% confidence interval [CI], 0.87 to 1.38; P=0.42). The mean 25(OH)D level at the end of the trial was 31.0 ng per milliliter in the vitamin D group and 10.7 ng per milliliter in the placebo group (mean between-group difference, 20.3 ng per milliliter; 95% CI, 19.9 to 20.6). Tuberculosis disease was diagnosed in 21 children in the vitamin D group and in 25 children in the placebo group (adjusted risk ratio, 0.87; 95% CI, 0.49 to 1.55). A total of 29 children in the vitamin D group and 34 in the placebo group were hospitalized for treatment of acute respiratory infection (adjusted risk ratio, 0.86; 95% CI, 0.52 to 1.40). The incidence of adverse events did not differ significantly between the two groups.'),\n",
       " ('https://nejm.jp/abstract/vol383.p359',\n",
       "  'モンゴルのビタミン D 欠乏状態の学齢児において，ビタミン D の摂取は，プラセボと比較して結核感染，結核症，急性呼吸器感染症のリスクを低下させなかった．（米国国立衛生研究所から研究助成を受けた．ClinicalTrials.gov 登録番号 NCT02276755）',\n",
       "  'https://www.nejm.org/doi/full/10.1056/NEJMoa1915176',\n",
       "  'Vitamin D supplementation did not result in a lower risk of tuberculosis infection, tuberculosis disease, or acute respiratory infection than placebo among vitamin D–deficient schoolchildren in Mongolia. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT02276755.)')]"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "JP=search_all(383)\n",
    "JP"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "pd.DataFrame(JP, columns = ['jp_url', 'jp_txt', 'en_url', 'en_txt']).to_csv(f'jp_en/total2.csv', index = False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 163,
   "metadata": {},
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'i' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-163-d1bb4a3efd57>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[0;32m----> 1\u001b[0;31m \u001b[0mdata\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mpd\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mDataFrame\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mi\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mcolumns\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;34m[\u001b[0m\u001b[0;34m'jp_url'\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m'jp_txt'\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m'en_url'\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m'en_txt'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m      2\u001b[0m \u001b[0mdata\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mhead\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;31mNameError\u001b[0m: name 'i' is not defined"
     ]
    }
   ],
   "source": [
    "data = pd.DataFrame(i, columns = ['jp_url', 'jp_txt', 'en_url', 'en_txt'])\n",
    "data.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
